Merck KGaA got the green light from the FDA to restart its late-stage lung cancer program for its therapeutic vaccine Stimuvax, which had been halted after a patient in a multiple myeloma trial contracted encephalitis in March. Licensed from Oncothyreon, the German pharma company has made a committed effort to bring in a trove of late-stage data on a range of cancers for its closely-watched therapeutic vaccine. Investigators now have an approval to ramp the lung cancer trials back up while leaving the breast cancer trial on hold for now. Story